Adam Kroetsch at Policy and Practice:
We need clinical trial abundance. When trials are slow and costly, it doesn’t just hurt the pharmaceutical industry that pays for the trials – it limits how many treatments reach patients and how quickly they arrive. Less expensive, more abundant trials would lead to more treatments and cures.
Experts across the field – from industry leaders to FDA commissioners – agree that clinical trials need reform. And many have offered solutions. But while proposed solutions are easy to find, we have not yet seen a clear explanation of exactly why clinical trials are so inefficient in the first place. Why does an industry that depends so heavily on trials allow them to become so slow and expensive? Without a diagnosis, we don’t know whether we are providing the right treatment.
So in this post, I’d like to take a deep dive: what are the root causes of inefficient trials? And how do we fix them?
More here.
Enjoying the content on 3QD? Help keep us going by donating now.